Where UroGen Pharma Stands With Analysts
Portfolio Pulse from Benzinga Insights
UroGen Pharma (NASDAQ:URGN) has received 2 bullish, 1 somewhat bullish, and 1 indifferent rating from analysts in the last quarter. The average price target is $21.5, slightly below the current price of $21.695. This average target has increased by 95.45% from the previous average of $11.00.
July 31, 2023 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
UroGen Pharma has received mixed ratings from analysts, with a price target slightly below its current price.
The average price target given by analysts is slightly below the current price of UroGen Pharma's stock, which could indicate a potential downside. However, the increase in the average price target from the previous average could suggest improving sentiment among analysts.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100